SELP and autoimmune thrombocytopenic purpura: P-selectin inhibitors, such as crizanlizumab, have demonstrated some efficacy in reducing platelet adhesion in other inflammatory diseases, suggesting their potential to limit platelet-T cell aggregation and mitigate chronic immune activation in ITP [90,91].